Breast cancer subtypes-primarily invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and ductal carcinoma in situ (DCIS)-are classified based on HER2 and hormone receptor status, influencing prognosis and treatment strategies [[4], [5], [6]]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.